8-K: Venus Concept Reports Q2 2024 Results: Revenue Declines but Operational Improvements Emerge

Venus Concept's Q2 2024 results show a revenue decrease of 17% year-over-year, but also a significant reduction in cash used in operations and improved gross margins.

Summary

• Venus Concept announced its financial results for the second quarter of 2024, showing a total revenue of $16.6 million, a 17% decrease compared to the same period last year.
• The company's revenue decline was primarily driven by a 29% decrease in international revenue and a 5% decrease in U.S. revenue.
• Gross profit decreased by 17% to $11.8 million, but gross margin improved slightly to 71.5%.
• Operating expenses decreased by 13% to $17.4 million, contributing to a 3% reduction in GAAP operating loss year-over-year.
• The company reported an adjusted EBITDA loss of $4.1 million, a 4% increase year-over-year despite the revenue decline.
• A debt-to-equity exchange transaction of $35 million was completed, significantly reducing the company's debt and bringing it back into compliance with Nasdaq's minimum equity requirement.
• Cash used in operations decreased by 37% year-over-year and 54% quarter-over-quarter, indicating improved cash flow management.
• The company expects total revenue for the three months ending September 30, 2024, to be at least $17.0 million, a 3% decline year-over-year but a 3% increase quarter-over-quarter.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the company's efforts to improve cash flow and reduce debt, despite a revenue decline. The company is taking steps to improve its financial position, but the lack of full-year guidance and continued losses temper the overall outlook.

Positives

• Gross margin improved to 71.5%, up from 70.8% in the same quarter last year.
• Operating expenses decreased by 13% year-over-year, showing improved cost management.
• Cash used in operations significantly decreased by 37% year-over-year and 54% quarter-over-quarter, indicating better cash flow management.
• The $35 million debt-to-equity exchange transaction significantly reduced the company's debt and brought it back into compliance with Nasdaq requirements.
• The company secured a medical device license in Canada for the Venus Versa Pro system.
• The company entered into a new strategic supply arrangement with Skin Laundry Holdings, Inc.
• The company's NEXThetics events saw a significant increase in popularity and attendance.

Negatives

• Total revenue decreased by 17% year-over-year to $16.6 million.
• International revenue decreased by 29% year-over-year.
• U.S. revenue decreased by 5% year-over-year.
• Adjusted EBITDA loss increased by 4% year-over-year to $4.1 million.
• Net loss attributable to stockholders was $20.0 million, or $3.05 per share, compared to a net loss of $7.4 million, or $1.35 per share, in the same quarter last year, which includes a pre-tax loss on debt extinguishment of $10.9 million.
• The company is not providing full-year 2024 financial guidance at this time.

Risks

• The company is facing macroeconomic headwinds that are challenging aesthetic capital equipment sales.
• Strategic initiatives to exit certain unprofitable direct markets are impacting revenue outside the U.S.
• Tighter third-party lending practices are negatively impacting capital equipment sales.
• The company is still experiencing losses, with a net loss of $20.0 million for the quarter.
• The company is not providing full-year 2024 financial guidance, indicating uncertainty about future performance.
• The company is currently in active dialogue with existing lenders and investors and evaluating strategic alternatives to maximize shareholder value, which could indicate financial instability.

Future Outlook

The company expects total revenue for the three months ending September 30, 2024, to be at least $17.0 million, representing a 3% decline year-over-year and a 3% increase quarter-over-quarter. The company is not providing full-year 2024 financial guidance at this time.

Management Comments

• Second quarter revenue results met the expectations we outlined on our first quarter report, said Rajiv De Silva, Chief Executive Officer of Venus Concept.
• Aesthetic capital equipment sales continue to be challenged by macroeconomic headwinds.
• Revenue results outside the U.S. continue to be impacted by the strategic initiatives to exit certain unprofitable direct market.
• We are enhancing our cash flow profile and remain focused on enhancing our balance sheet condition and enhancing the Company's foundation to support long-term, sustainable, profitability and growth in the future.

Industry Context

The medical aesthetics industry is facing macroeconomic challenges, impacting capital equipment sales. Venus Concept's strategic shift to exit unprofitable markets and focus on cash flow improvement aligns with broader industry trends of companies seeking sustainable growth and profitability.

Comparison to Industry Standards

• While Venus Concept's revenue declined by 17%, other medical aesthetic companies like Cutera and InMode have also experienced varying degrees of growth and challenges in recent quarters, reflecting the broader macroeconomic pressures.
• Venus Concept's gross margin of 71.5% is competitive with industry standards, where companies like Syneron Candela typically report gross margins in the 60-70% range.
• The company's focus on reducing operating expenses and improving cash flow is a common strategy among medical device companies facing financial pressures, similar to actions taken by companies like Lumenis in their restructuring efforts.
• The debt-to-equity exchange transaction is a significant step for Venus Concept, as many companies in the medical device sector with high debt levels have faced challenges in maintaining financial stability, such as the restructuring efforts of companies like Zeltiq Aesthetics in the past.

Legal Proceedings

• The Canada Revenue Agency (CRA) has assessed a denial of Canada Emergency Wage Subsidy (CEWS) claims made by the Company in 2020 and is requesting repayment of $418,000. The Company disputes the CRA assessment and intends to challenge this matter.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and net loss, but encouraged by the debt reduction and improved cash flow.
• Employees may be affected by restructuring activities designed to improve the company's operations and cost structure.
• Customers may benefit from the company's new product launches and strategic partnerships.
• Suppliers may be impacted by the company's efforts to improve its financial position.
• Creditors may be reassured by the company's debt reduction efforts.

Next Steps

• The company will continue to execute its transformational plan.
• The company will continue to evaluate strategic alternatives to maximize shareholder value.
• The company will host a conference call to discuss the results of the quarter.

Key Dates

Keywords

medical aesthetics, financial results, revenue, EBITDA, debt reduction, cash flow, Venus Concept, medical devices, operating expenses, gross margin